Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 967-976

  Coelmont, Lotte ^a   Kaptein, Suzanne ^a   Paeshuyse, Jan ^a   Vliegen, Inge ^a   Dumont, Jean Maurice ^b   Vuagniaux, Gregoire ^b   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b DEBIOPHARM SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; NS3 PROTEASE INHIBITOR; NS5B POLYMERASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REPLICON; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOPHILINS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; HEPACIVIRUS; HEPATITIS C; HUMANS; REPLICON; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 62949181285     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00939-08     Document Type: Article

References (64)

1. Anonymous. 2008. Pharmasset announces R7128 achieves 85% rapid virologic response in a 4-week combination study for the treatment of chronic hepatitis. Pharmasett. Princeton. NJ. http://investor.pharmasset.com/ releasedetail.cfm?ReleaseID=284920.
2. Anonymous. 2008. InterMune announces continuing progress on ITMN-191 (R7227). InterMune. Brisbane. CA. http://phx.corporate-ir.net/phoenix. zhtml?c=100067&p=irol-newsArticle&ID=1092155&highlight=.
3. Anonymous. 2007. Initial results of phase II study with HCV protease inhibitor boceprevir in treatment-naive hepatitis C patients show a high rate of early virologic response. Schering-Plough, Kenilworth, NJ. http:/www.schering-plough.com/schering-plough/news/release.jsp?releaseID= 1064540.
4. Baba, M., R. Pauwels, J. Balzarini, P. Herdewijn, E. De Clercq, and J. Desmyter. 1987. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31:1613-1617.
5. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76:13001-13014.
6. Carroll, S. S., and D. B. Olseu. 2006. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets 6:17-29.
7. Carroll, S. S., J. E. Tomassini, M. Bosserman, K. Getty, M. W. Stahlhut, A. B. Eldrup, B. Bhat, D. Hall, A. L. Simcoe, R. LaFemina, C. A. Rutkowski, B. Wolanski, Z. Yang, G. Migliaccio, R. De-Francesco, L. C. Kuo, M. Mac-Coss, and D. B. Olsen. 2003. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984.
8. Chatterji, U., M. D. Bobardt, R. Stanfield, R. G. Ptak, L. A. Pallansch, P. A. Ward, M. J. Jones, C. A. Stoddart, P. Scalfaro, J. M. Dumont, K. Besseghir, B. Rosenwirth, and P. A. Gallay. 2005. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and trim-cyclophilin resistant in owl monkey cells. J. Biol. Chem. 280:40293-40300.
9. Chung, R. T., M. Gale, Jr., S. J. Polyak, S. M. Lemon, T. J. Liang, and J. H. Hoofnagle. 2008. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 47:306-320.
10. Clark, J. L., J. C. Mason, L. Hollecker, L. J. Stumer, P. M. Tharnish, T. R. McBrayer, M. J. Otto, P. A. Furman, R. F. Schinazi, and K. A. Watanabe. 2006. Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C- methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 16:1712-1715.
11. Coelmont, L., J. Paeshuyse, M. P. Windisch, E. De Clercq, R. Barten-schlager, and J. Neyts. 2006. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine. the active component of valopicitabine. Antimicrob. Agents Chemother. 50:3444-3446.
12. Craxi, A., and A. Licata. 2003. Clinical trial results of peginterferons in combination with ribavirin. Semin. Liver Dis. 23(Suppl. l):35-46.
13. De Clercq, E., and J. Neyts. 2009. Antiviral agents acting as DNA or RNA chain terminators, p. 53-84. In H. G. Krausslich and R. Bartenschlager (ed.), Handbook of experimental pharmacology, vol. 189. Springer. Berlin, Germany.
14. De Francesco, R., and G. Migliaccio. 2005. Challenges and successes in developing new therapies for hepatitis C. Nature 436:953-960.
15. Eldrup, A. B., C. R. Allerson, C. F. Bennett, S. Bera, B. Bhat, N. Bhat, M. R. Bosserman, J. Brooks, C. Burlein, S. S. Carroll, P. D. Cook, K. L. Getty, M. MacCoss, D. R. McMasters, D. B. Olsen, T. P. Prakash, M. Prhavc, Q. Song, J. E. Tomassini, and J. Xia. 2004. Structure-activity relationship of purineribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 47:2283-2295.
16. Faucher, A. M., M, D. Bailey, P. L. Beaulieu, C. Brochu, J, S. Duceppe, J, M. Ferland, E. Ghiro, V. Gorys, T. Halmos, S. H. Kawai, M. Poirier, B. Simo-neau, Y. S. Tsantrizos, and M. Llinas-Brunet 2004. Synthesis of B1LN 2061. an HCV NS3 protease inhibitor with proven antiviral effect in humans. Org. Lett. 6:2901-2904.
17. Flisiak, R-, S. V. Feinman, M. Jablkowski, A. Horban, W. Kryczka, W. Halota, J. E. Heathcote, G, Mazzella, C. Vandelli, J. S, Liz, R, Crabbe, P. Scalfaro, and H. Porchet. 2008. Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio-025 in combination with pegylated interferon alpha-2a in treatment naive chronic HCV patients. J. Hepatol. 48(Suppl. 2):S62.
18. Flisiak, R., J. M. Dumont, and R. Crabbe. 2007. Cyclophilin inhibitors in hepatitis C viral infection. Expert. Opin. Investig. Drugs 16:1345-1354.
19. Flisiak, R., A. Horban, P. Gallay, M. Bobardt, S. Selvarajah, A. Wiercinska-Drapalo, E. Siwak, I. Cielniak, J. Higersberger, J. Kierkus, C. Aeschlimann, P. Grosgurin, V. Nicolas-Metral, J. M. Dumont, H. Porchet, R. Crabbe, and P. Scalfaro. 2008. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47:817-826.
20. Gopalsamy, A., A. Aplasca, G. Ciszewski, K. Park, J. W. Ellingboe, M. Orlowski, B. Feld, and A. Y. Howe. 2006. Design and synthesis of 3.4-dihydro-lH-[l]-benzothieno[2,3-c]pyran and 3,4-dihydro-lH-pyrano[3,4-djbenzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg. Med. Chem. Lett. 16:457-460.
21. Hashimoto, H., K. Mizutani, and A. Yoshida. 2005. Fused cyclic compounds and medicinal use thereof. Report WO/2003/000254. World Intellectual Property Organization, Geneva, Switzerland.
22. Hinrichsen, H., Y. Benhamou, H. Wedemeyer, M. Reiser, R. E. Sentjens, J. L. Calleja, X. Forns, A. Erhardt, J. Cronlein, R. L. Chaves, C. L. Yong, G. Nehmiz, and G. G. Steinmann. 2004. Short-term antiviral efficacy of BILN 2061. a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:1347-1355.
23. Houck, D. R., and S. Hopkins. 2006. Preclinical evaluation of SCY-635, a cyclophilin inhibitor with potent anti-HCV activity. Hepatology 44:534A.
24. Hubler, F., T. Ruckle, L. Patiny, T. Muamba, J. F. Guichou, M. Mutter, and R. Wenger. 2000. Synthetic routes to NEtXaa4-cyclosporin A derivates as potential anti-HlV I drugs. Tetrahedron Lett. 41:7193-7196.
25. Inoue, K., K. Sekiyama, M. Yamada, T. Watanabe, H. Yasuda, and M. Yoshiba. 2003. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. 38:567-572.
26. Inoue, K., T. Umehara, U. T. Ruegg, F. Yasui, T. Watanabe, H. Yasuda, J. M. Dumont, P. Scalfaro, M. Yoshiba, and M. Kohara. 2007. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45:921-928.
27. Kaul, A., S. Stauffer, J. Schmitt, T. Pertel, J. Luban, and R. Bartenschlager. 2008. Role of cyclophilins in hepatitis C virus replication, abstr. P-218. Abstr. 15th Int. Symp. Hepatitis C Virus Related Viruses.
28. Klumpp. K., G. Kalayanov, H. Ma, S. Le Pogam, V. Leveque, W. R. Jiang, N. Inocencio, A. De Witte, S. Rajyaguru, E. Tai, S. Chanda, M. R. Irwin, C. Sund, A. Winqist, T. Maltseva, S. Eriksson, E. Usova, M. Smith, A. Alker, I. Najera, N. Cammack, J. A. Martin, N. G. Johansson, and D. B. Smith. 2008. 2'-Deoxy-4'-azido nucleoside analogs are highly potent inhibitors of HCV replication despite the lack of 2'-alpha hydroxyl groups. J. Biol. Chem. 283:2167-2175.
29. Klumpp, K., V. Leveque, S. Le Pogam, H. Ma, W. R. Jiang, H. Kang, C. Granycome, M. Singer, C. Laxton, J. Q. Hang, K. Sarma, D. B. Smith, D. Heindl, C. J. Hobbs, J. H. Merrett, J. Symons, N. Cammack, J. A. Martin, R. Devos, and I. Najera. 2006. The novel nucleoside analog R1479 (4'-azido-cytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281:3793-3799.
30. Kwong, A. D., S. Cowherd, and P. Mueller. 2006. Beyond interferon and ribavirin: antiviral therapies for hepatitis C virus. Drug Discov. Today Ther. Strategies 3:211-220.
31. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
32. Le Pogam, S., H. Kang, S. F. Harris, V. Leveque, A. M. Giannetti, S. Ali, W. R. Jiang, S. Rajyaguru, G. Tavares, C. Oshiro, T. Hendricks, K. Klumpp, J. Symons, M. F. Browner, N. Cammack, and I. Najera. 2006. Selection and characterization of replicon variants dually resistant to thumb-and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C vims. J. Virol. 80:6146-6154.
33. Lin, C, C. A. Gates, B. G. Rao, D. L. Brennan, J. R. Fulghum, Y. P. Luong, J. D. Frantz, K. Lin, S. Ma, Y. Y. Wei, R. B. Perni, and A. D. Kwong. 2005. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 280: 36784-36791.
34. Lin, C, K. Lin, Y. P. Luong, B. G. Rao, Y. Y. Wei, D. L. Brennan, J. R. Fulghum, H. M. Hsiao, S. Ma, J. P. Maxwell, K. M. Cottrell, R. B. Perni, C. A. Gates, and A. D. Kwong. 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279:17508- 17514.
35. Lohmann, V., F. Korner, A. Dobierzewska, and R. Bartenschlager. 2001. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:1437-1449.
36. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
37. Ma, S., J. E. Boerner, C. TiongYip, B. Weidmann, N. S. Ryder, M. P. Cooreman, and K. Lin. 2006. N1M811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C vims alone or in combination with alpha interferon. Antimicrob. Agents Chemother. 50:2976-2982.
38. Manns, M. P., G. R. Foster, J. K. Rockstroh, S. Zeuzem, F. Zoulim, and M. Houghton. 2007. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov. 6:991-1000.
39. Modi, A. A., and J. H. Hoofnagle. 2007. New therapies for hepatitis C. Hepatology 46:615-617.
40. Nakagawa, M., N. Sakamoto, N. Enomoto, Y. Tanabe, N. Kanazawa, T. Koyama, M. Kurosaki, S. Maekawa, T. Yamashiro, C. H. Chen, Y. Itsui, S. Kakinuma, and M. Watanabe. 2004. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. 313:42-47.
41. Nakagawa, M., N. Sakamoto, Y. Tanabe, T. Koyama, Y. Itsui, Y. Takeda, C. H. Chen, S. Kakinuma, S. Oooka, S. Maekawa, N. Enomoto, and M. Watanabe. 2005. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 129:1031-1041.
42. Neyts, J. 2006. Selective inhibitors of hepatitis C virus replication. Antivir. Res. 71:363-371.
43. Paeshuyse, J., A. Kaul, E. De Clercq, B. Rosenwirth, J. M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts. 2006. The non-immunosuppres-sive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C vims replication in vitro. Hepatology 43:761-770.
44. Pancheva, S. N. 1991. Potentiating effect of ribavirin on the anti-herpes activity of acyclovir. Antivir. Res. 16:151-161.
45. Perni, R. B., S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y. P. Luong, B. G. Rao, W. P. Taylor, J. A. Thomson, R. D. Tung, Y. Wei, A. D. Kwong, and C. Lin. 2006. Preclinical profile of VX-950. a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50:899-909.
46. Pierra, C, A. Amador, S. Benzaria, E. Cretton-Scott, M. D'Amours, J. Mao, S. Mathieu, A. Moussa, E. G. Bridges, D. N. Standring, J. P. Sommadossi, R. Storer, and G. Gosselin. 2006. Synthesis and pharmacokinetics of valo-picitabine (NM283). an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J. Med. Chem. 49:6614-6620.
47. Prichard, M. N., and C. Ship man, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
48. Ptak, R. G., P. A. Gallay, D. Jochmans, A. P. Halestrap, U. T. Ruegg, L. A. Pallansch, M. D. Bobardt, M. P. de Bethune, J. Neyts, E. De Clercq, J. M. Dumont, P. Scalfaro, K. Besseghir, R. M. Wenger, and B. Rosenwirth. 2008. nhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025. a novel cyclophilin binding agent. Antimicrob. Agents Che mothe r. 52:1302-1317.
49. Rosenwirth, B., A. Billich, R. Datema, P. Donatsch, F. Hammerschmid, R. Harrison, P. Hiestand, H. Jaksche, P. Mayer, and P. Peichl. 1994. Inhibition of human immunodeficiency vims type 1 replication by SDZ N1M 811. a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. 38:1763-1772.
50. Sarrazin, C, R. Rouzier, F. Wragner, N. Forestier, D. Larrey, S. K. Gupta, M. Hussain, A. Shah, D. Cutler, J. Zhang, and S. Zeuzem. 2007. SCH 503034, a novel hepatitis C vims protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132:1270-1278.
51. Simmen, K., O. Lenz, T. S. Lin, G. Fanning, P. Raboisson, H. de Kock, H. G. van't Klooster, A. Rosenquist, M. Edlund, M. Nilsson, L. Vrang, and B. Samuelsson. 2007. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor, TMC435350. Hepatology 46:857A.
52. Smith, D. B., J. A. Martin, K. Klumpp, S. J. Baker, P. A. Blomgren, R. Devos, C. Granycome, J. Hang, C. J. Hobbs, W. R. Jiang, C. Laxton, S. Le Pogam,V. Leveque, H. Ma, G. Maile, J. H. Merrett, A. Pichota, K. Sarma, M. Smith, S. Swallow, J. Symons, D. Vesey, I. Najera, and N. Cammack. 2007. Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg. Med. Chem. Lett. 17:2570-2576.
53. Stuyver, L. J., T. R. McBrayer, P. M. Tharnish, J. Clark, L. Hollecker, S. Lostia, T, Nachman, J. Grier, M. A. Bennett, M. Y. Xie, R. F. Schinazi, J. D. Morrey, J. L. Julander, P. A. Furman, and M. J. Otto. 2006. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro- 2'-C-meth-ylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 17:79-87.
54. Summa, V. 2005. VX-950 (Vertex/Mitsubishi). Curr. Opin. Investig. Drugs 6:831-837.
55. Timm, J., and M. Roggendorf. 2007. Sequence diversity of hepatitis C vims: implications for immune control and therapy. World J. Gastroenterol. 13: 4808-4817.
56. Verloes, R., K. A. Farha, A. van Vliet, G. van't Klooster, F. Aharchi, K. Marien, H. de Kock, and K. Simmen. 2007. Results of a phase 1 placebo-controlled trial in healthy volunteers to examine the safety, tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing. Hepatology 46:823A.
57. Vogt, M. W., K. L. Hartshorn, P. A. Furman, T. C. Chou, J. A. Fyfe, L. A. Coleman, C. Crumpacker, R. T. Schooley, and M. S. Hirsch. 1987. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235: 1376-1379.
58. Vrolijk, J. M., A. Kaul, B. E. Hansen, V. Lohmann, B. L. Haagmans, S. W. Schalm, and R. Bartenschlager. 2003. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 110:201-209.
59. Watashi, K., M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno. 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282-1288.
60. Windisch, M. P., M. Frese, A. Kaul, M. Trippler, V. Lohmann, and R. Bartenschlager. 2005. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J. Virol. 79:13778-13793.
61. Yang, F., J. M. Robotham, H. B. Nelson, A. Irsigler, R Kenworthy, and H. Tang. 2008. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 82:5269-5278.
62. Yeni, P. 2006. Update on HAART in HIV. J. Hepatol. 44(Suppl. 1):S100-S103.
63. Ying, C, E. De Clercq, and J. Neyts. 2000. Ribavirin and mycophenolic acid potentiate the activity of guanine-and diaminopurine-based nucleoside analogues against hepatitis B virus. Antivir. Res. 48:117-124.
64. Zoulim, F., M. Chevallier, M. Maynard, and C. Trepo. 2003. Clinical consequences of hepatitis C virus infection. Rev. Med. Virol. 13:57-68.